Morphic’s lead product is an oral small molecule inhibitor that is a potential inflammatory bowel disease treatment, according to a July 8 news release from Eli Lilly. The biopharmaceutical business is also testing therapies for autoimmune diseases, pulmonary hypertensive diseases, fibrotic diseases and cancer.
Both company’s boards have approved the transaction, which is expected to finalize in the third quarter of 2024.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.